Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.33 | N/A | -8.55% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.33 | N/A | -8.55% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over current performance but remains focused on future developments. They did not provide specific guidance for upcoming quarters.
Management acknowledged challenges in meeting expectations.
They emphasized ongoing efforts to improve product pipeline.
The earnings report indicates that Biocryst Pharmaceuticals is facing challenges, particularly reflected in its EPS miss. The stock's significant drop of 18.1% suggests investor disappointment and concern over the company's current trajectory. Without guidance, uncertainty remains about the company's future performance and strategy.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021